The Rise of Nicotine Toothpicks: Why Oral Nicotine Is Fragmenting Into Ever-Smaller Niches

In a coffee shop in Stockholm, a customer tucks a slim white pouch under their upper lip—discreet, odorless, invisible. In a co-working space in Austin, a different customer stirs a nicotine-infused toothpick between their teeth, the mild cinnamon flavor and 3mg of nicotine providing what the packaging describes as 'clean focus.' In a London pharmacy, a third customer purchases nicotine lozenges in mint flavor, part of a structured quit attempt. All three are using 'oral nicotine products,' but the products, the users, the use cases, and the regulatory frameworks are entirely different. The oral nicotine category, once a simple landscape of pharmaceutical gum and lozenge, is fragmenting into an ever-proliferating array of formats, each targeting a specific consumer niche with a specific value proposition. The fragmentation is both an opportunity (more paths away from smoking) and a challenge (how to regulate a category that's dissolving into a thousand micro-products).

The drivers of oral nicotine fragmentation are technological, regulatory, and cultural. Technologically, the same pharmaceutical formulation advances that produced nicotine gum and lozenges are now being applied to new formats—toothpicks (wood infused with nicotine salts), dissolving tablets (similar to breath strips), and 'snus-lite' pouches with lower nicotine and milder flavors. Regulatory arbitrage is a major factor: products that don't fit neatly into existing categories ('tobacco product,' 'pharmaceutical,' 'food') can enter markets with minimal pre-market review, creating a first-mover advantage for novel formats. And culturally, the destigmatization of nicotine—driven by the 'wellness nicotine' marketing of brands like Lucy and NIIN—has created demand for products that deliver nicotine discreetly, without smoke or vapor, in formats that feel more like a consumer good than a drug. The cultural shift is particularly significant: for the first time, non-trivial numbers of never-smokers are initiating nicotine use through oral products, attracted by the cognitive-enhancement and wellness positioning that combustible and vapor products can't credibly claim.

The regulatory challenge of oral nicotine fragmentation mirrors the challenge of vaping fragmentation, but with less public visibility because the products are less visible in use. Regulators are still oriented toward product categories—'cigarettes,' 'smokeless tobacco,' 'e-cigarettes'—while the oral nicotine market is evolving toward product continua where the boundaries between categories blur. Is a nicotine toothpick a 'tobacco product' under the FDA's authority if the nicotine is tobacco-derived but the delivery format has no relationship to any traditional tobacco product? Is a nicotine pouch a 'pharmaceutical' if it's marketed for focus and energy rather than cessation? The category questions are not academic—they determine which regulatory framework applies, what pre-market requirements exist, and what claims manufacturers can make. And they're being asked in an environment where the products are already on the market, consumers are already using them, and the regulatory answers may take years to develop.

The public health implications of oral nicotine fragmentation are genuinely uncertain and likely heterogeneous across products and populations. For smokers, the proliferation of oral nicotine products is almost certainly positive: more options mean more opportunities to find a product that works for a given individual's preferences, increasing the probability of successful switching. For never-smokers, the proliferation is more concerning: easy access to discrete, socially acceptable nicotine products lowers the barrier to initiation, and the cognitive-enhancement marketing explicitly targets never-users who want the focus and energy benefits without the stigma of smoking. The net population effect depends on the balance between smokers who switch (health benefit) and never-users who initiate (health cost), and that balance is unknown and likely to remain unknown for years because the products are too new and the surveillance systems aren't designed to track them.

The opportunistic industry response to the regulatory fragmentation is creating a market where the least regulated products are growing fastest. Nicotine pouches, which contain no tobacco and can be positioned as 'tobacco-free nicotine,' are expanding rapidly in markets where vaping is heavily restricted—Australia, parts of the EU, several U.S. states. Nicotine toothpicks and dissolving tablets occupy an even grayer area, with almost no specific regulation in most jurisdictions. The market is selecting for regulatory arbitrage: the products that face the lowest regulatory burden have a competitive advantage, regardless of their relative risk profile or their population-level health impact. This dynamic is not accidental—it's the predictable consequence of a regulatory system organized around product categories rather than risk characteristics, and it will continue until the system shifts toward risk-proportionate regulation that applies consistently across product formats.

The solution, increasingly advocated by harm-reduction researchers, is a unified regulatory framework for all non-combustible nicotine products that establishes product standards (nicotine concentration limits, ingredient restrictions, quality requirements), marketing restrictions (no youth targeting, no unsubstantiated health claims), and retail access controls (age-gated sales, no self-service displays) while creating a risk-proportionate tax structure that incentivizes movement down the risk continuum. This framework would treat nicotine pouches, gum, lozenges, toothpicks, and dissolving tablets as a single regulatory category differentiated from combustible tobacco and from pharmaceutical cessation products. It would eliminate the regulatory arbitrage that currently drives fragmentation while preserving the consumer choice that makes the oral nicotine market effective for smoking cessation. It would require legislation in most jurisdictions, and legislation requires political will that—as the vaping experience demonstrates—is slow to materialize for nicotine products.

The oral nicotine fragmentation story is, in microcosm, the story of nicotine in the 21st century: innovation outpacing regulation, consumers navigating a landscape that changes faster than the rules that govern it, and public health trying to evaluate products whose population-level effects won't be known for years. The fragmentation is neither good nor bad in itself. It's a structural feature of a market where regulatory categories are product-based, technology is format-agnostic, and consumer preferences are increasingly fragmented. The policy challenge is to build a regulatory framework that's as adaptable as the market it governs—one that regulates based on risk characteristics rather than product names, that can accommodate novel formats without requiring new legislation for each one, and that creates incentives for the lowest-risk products to be the most accessible and affordable. That framework doesn't exist yet. The oral nicotine market isn't waiting for it.